Project: Improved treatments of Acute Myeloid Leukaemias by Personalized Medicine
Acronym | AML_PM (Reference Number: ERAPERMED2018-116) |
Duration | 01/03/2019 - 28/02/2022 |
Project Topic | Acute Myeloid Leukemia (AML) is a highly aggressive cancer with few treatment options for the majority of patients. As alterations in cell signalling are a hallmark of more than half of the AML patients, drugs targeting signalling pathways are being developed. A major problem is the heterogeneity of AML between patients and within individual patients through manifold development of cancer cell subclones, making it difficult to provide appropriate treatment options. Our multidisciplinary, translational approach with access to AML biobanks as well as longitudinal data from ongoing clinical trials, provides in conjunction with data generated in the project a rich high quality source for big data analytics and mathematical modelling. Through collaboration with infrastructures for sensitive data and FAIRDOM, we establish procedures for data management, harmonisation and quality assessment that ensure data interoperability, reusability and patient security. The progress in the project are communicated to the public including the involvement of patient organizations. The development of innovative computational tools for integrative analysis of multiomics data provide insights into pathomechanisms and pave the way for early identification of AML patients that respond to novel signalling-targeted drugs. The subclonal architecture of individual AML patients and their signalling status are mapped by mass and flow cytometry. The quantitative omics and clinical data is combined with methods for machine learning to develop AML classifier. Dynamic pathway models are established for each AML subclass to predict clonal development and optimal treatment for individual patients that are tested in vitro and in vivo in pre-clinical models and by proof-of-concept validation in patients. The personalized medicine approach pursued in the project aims at validated bioinformatics and experimental pipelines for clinical decision-making and for tailoring treatment for individual AML patients. |
Network | ERA PerMed |
Call | 1st Joint Transnational Call for Proposals (2018) |
Project partner
Number | Name | Role | Country |
---|---|---|---|
1 | University of Bergen | Coordinator | Norway |
2 | Helse Bergen Haukeland University Hospital Health Trust | Partner | Norway |
3 | University Medical Center Groningen, University of Groningen | Partner | Netherlands |
4 | German Cancer Research Center (DKFZ) | Partner | Germany |
5 | University of Freiburg | Partner | Germany |
6 | Medical Center Leeuwarden | Partner | Netherlands |
7 | University of Toronto | Partner | Canada |